Core Viewpoint - The recent fuel price increase in Thailand is expected to significantly impact domestic market-oriented industries, particularly those sensitive to oil prices [1] Industry Impact - The Thai Oil Fuel Fund Committee approved a nationwide fuel price increase of 6 Thai Baht per liter, which will adversely affect oil-sensitive and domestic demand-driven sectors such as transportation, commercial, construction, and non-essential consumer goods [1] - Conversely, the energy sector is anticipated to perform well as rising oil prices will directly boost profitability in this industry [1] Preferred Stocks - The brokerage's preferred stocks in light of the fuel price increase include PTT, PTT Exploration and Production, True Corp., and Bangkok Dusit Medical Services [1]

Core Insights - Over 70% of new products from Li Ning were launched on Tmall in the past year, generating at least 2 billion in revenue from the Tmall flagship store [1] - The company values not only the sales certainty on Tmall but also the certainty regarding target demographics and operational forecasts [1] - Tmall provides a sense of "security" for Li Ning, allowing the brand to leverage platform data tools to accurately assess market size and consumer assets before launching new products [1] Company Strategy - Li Ning's Tmall flagship store has over 20 million members, which enhances its ability to predict market trends and consumer preferences [1] - The use of data tools enables the brand to transform the process of identifying potential bestsellers from a guessing game into a more reliable strategy, allowing for greater investment in core R&D resources for new products [1]

Core Viewpoint - CITIC Securities reported significant growth in both revenue and net profit for the year 2025, with net profit increasing by nearly 40% and total assets surpassing 2 trillion yuan for the first time, establishing itself as the first securities company in China to achieve this milestone [1][6]. Financial Performance - In 2025, CITIC Securities achieved operating revenue of 74.85 billion yuan, a year-on-year increase of 28.79% [1][6]. - The net profit attributable to shareholders reached 30.08 billion yuan, marking a substantial year-on-year increase of 38.58% [1][6]. - Total assets grew to 2.08 trillion yuan, reflecting a 21.70% increase from the previous year [1][6]. Shareholder Returns - The company plans to distribute a cash dividend of 7.00 yuan per 10 shares (tax included) for the year 2025 [1][6]. - CITIC Securities has maintained continuous cash dividends for 24 years since its listing, with total dividends exceeding 93 billion yuan [1][6]. Revenue Contribution by Business Segment - Securities investment business generated 27.61 billion yuan, accounting for 36.9% of total revenue [7]. - Brokerage business revenue was 20.79 billion yuan, contributing 27.8% [7]. - Asset management business revenue reached 14.29 billion yuan, representing 19.1% [7]. - Investment banking business generated 6.06 billion yuan, making up 8.1% [7]. - Other business segments contributed 6.11 billion yuan, accounting for 8.2% [7]. Growth Drivers - The investment banking segment experienced the highest growth rate, with revenue increasing by 50.12%, driven by a significant rise in A-share financing activities [2][7]. - A-share equity financing issuance increased by 245.42%, with CITIC Securities completing 72 underwriting projects totaling 270.65 billion yuan, capturing a market share of 24.36% [2][7]. - Brokerage and asset management businesses grew by 25.55% and 24.59%, respectively, benefiting from increased market activity and asset management expansion [2][8]. International Business Growth - International business revenue reached 15.52 billion yuan, growing by 41.75%, significantly outpacing domestic business growth of 25.79% [3][9]. - The total assets of overseas subsidiaries amounted to 490.66 billion yuan, representing 23.57% of the group's total assets [3][9]. - The company completed 91 overseas equity projects, ranking second in Hong Kong IPO sponsorship and first in offshore bond underwriting [3][9]. Compliance Issues - Prior to the annual report release, CITIC Securities' Hong Kong subsidiary was involved in a significant insider trading scandal, with allegations of bribery and information leakage [4][10]. - The company has faced multiple regulatory warnings during the reporting period, related to issues such as margin financing management and internal controls [4][10].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Longxin Fund has a significant holding in Tiger Med, with its Longxin Xianrui Mixed A Fund (519937) holding 50,000 shares, representing 0.71% of the fund's net value, making it the seventh-largest holding [2][5]. - The fund has realized a floating profit of approximately 127,000 CNY today, with a total floating profit of 162,000 CNY during the three-day increase [2][5]. - The Longxin Xianrui Mixed A Fund was established on June 2, 2016, with a current size of 16.30 million CNY. Year-to-date returns are 1.52%, with a one-year return of 5.08% and a cumulative return of 43.7% since inception [2][5]. Fund Manager Performance - The fund manager, Ye Song, has a tenure of 15 years and 3 days, managing assets totaling 1.397 billion CNY, with the best fund return during his tenure being 98.51% and the worst being -16.83% [3][6]. - Co-manager Cheng Fang has a tenure of 5 years and 88 days, managing assets of 538 million CNY, with the best return of 16.42% and the worst return of 1.3% during his tenure [3][6].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yuanxin Yongfeng have heavily invested in Tiger Med, holding a total of 293,400 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of 745,200 CNY, with a total floating profit of 950,600 CNY over the past three days [2][8]. - Yuanxin Yongfeng Multi-Strategy Fund (004148) holds 185,900 shares, representing 3.18% of the fund's net value, while Yuanxin Yongfeng Consumption Upgrade Fund (004934) holds 107,500 shares, accounting for 3.3% of the fund's net value [3][7].

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, established on December 15, 2004, and listed on August 17, 2012. The company specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, regulatory submissions, and various medical services [1][7]. Stock Performance - On March 27, Tiger Med's stock rose by 5%, reaching a price of 53.32 CNY per share, with a trading volume of 696 million CNY and a turnover rate of 2.35%. The total market capitalization is 45.91 billion CNY. The stock has experienced a cumulative increase of 6.82% over the past three days [1][7]. Shareholder Insights - E Fund's ChiNext ETF (159915) is among the top ten shareholders of Tiger Med, having reduced its holdings by 1.88 million shares in the third quarter, now holding 11.26 million shares, which represents 1.63% of the circulating shares. The estimated floating profit today is approximately 28.60 million CNY, with a total floating profit of 36.48 million CNY over the past three days [2][8]. Fund Performance - E Fund's ChiNext ETF (159915) has a total asset size of 100.45 billion CNY, with a year-to-date return of 2.38%, ranking 1280 out of 5563 in its category. Over the past year, it has achieved a return of 55.52%, ranking 386 out of 4429, and since inception, it has returned 274.08% [2][8]. Fund Holdings - Six funds under E Fund have significant holdings in Tiger Med, totaling 2.56 million shares. Based on the previous day's closing price of 50.78 CNY, the estimated floating profit today is around 650,660 CNY, with a total floating profit of 829,980 CNY over the past three days [4][10]. Fund Manager Profiles - The fund managers of E Fund's ChiNext ETF (159915) are Cheng Xi and Liu Shurong. Cheng has been in the position for 9 years and 327 days, managing assets totaling 252.07 billion CNY, with the best return during his tenure being 131.04%. Liu has been managing 127.68 billion CNY for 8 years and 255 days, achieving a best return of 194.12% [3][9].

Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xiangcai Fund has a significant holding in Tiger Med, with the Xiangcai Changxing Flexible Allocation Mixed A Fund (009169) holding 20,900 shares, representing 4.73% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 53,100 CNY today and a total of 67,700 CNY during the three-day price increase [2][5]. - The Xiangcai Changxing Flexible Allocation Mixed A Fund was established on April 23, 2020, with a current size of 9.6681 million CNY. Year-to-date, it has incurred a loss of 5.96%, ranking 7640 out of 8898 in its category, while it has achieved a 7.24% return over the past year, ranking 5586 out of 8181 [2][5]. Fund Manager Performance - The fund managers of Xiangcai Changxing Flexible Allocation Mixed A are Che Guanglu and Bao Jiamin. Che has a tenure of 14 years and 30 days, managing assets totaling 489 million CNY, with the best fund return of 54.67% and the worst return of -40.29% during his tenure [3][6]. - Bao has a tenure of 2 years and 24 days, managing assets of 662 million CNY, with the best fund return of 60.96% and the worst return of -12.82% during her tenure [3][6].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][6]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6][7]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [7]. Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) has entered the top ten circulating shareholders of Tiger Med, holding 8.78 million shares, which is 1.27% of the circulating shares. The estimated floating profit today is approximately 22.30 million CNY, with a total floating profit of 28.44 million CNY over the three-day increase [2][8]. - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.26 billion CNY. Year-to-date, it has experienced a loss of 3.16%, ranking 3698 out of 5563 in its category, while it has gained 17.24% over the past year, ranking 2622 out of 4429 [2][8]. Fund Performance - The fund manager of Huatai-PB CSI 300 ETF is Liu Jun, who has a tenure of 16 years and 301 days, managing assets totaling 550.93 billion CNY. The best fund return during his tenure is 205.53%, while the worst is -45.64% [3][8]. - Huatai-PB Medical Health A (005805) has increased its holdings in Tiger Med by 5,950 shares, totaling 273,500 shares, which represents 5.02% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is about 694,700 CNY, with a total floating profit of 886,100 CNY over the three-day increase [4][9]. - The Huatai-PB Medical Health A fund was established on June 25, 2018, with a current scale of 251 million CNY. It has incurred a loss of 5.46% year-to-date, ranking 7497 out of 8898, while gaining 4.27% over the past year, ranking 6365 out of 8181 [4][9]. Fund Manager Insights - The fund manager of Huatai-PB Medical Health A is Zhang Hong, who has a tenure of 6 years and 145 days, managing assets totaling 2.21 billion CNY. The best fund return during his tenure is 105.24%, while the worst is -19.01% [5][10].

Core Viewpoint - Tiger Med has seen a significant stock price increase, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yinhua Fund have significant holdings in Tiger Med, totaling 6.2985 million shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 15.9982 million CNY, with a total floating profit of 20.4072 million CNY over the past three days [2][7]. - The "Innovation Drug" fund holds 6.25881 million shares, representing 0.8481% of the circulating shares and 2.86% of the fund's net value, while the "Yinhua Healthcare Mixed A" fund holds 39,700 shares, accounting for 0.0053% of the circulating shares and 5.37% of the fund's net value [3][8].

Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under China International Capital Corporation (CICC) holds a significant position in Tiger Med. The CICC New Medicine A Fund (006981) held 89,800 shares in the fourth quarter, representing 5.9% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 228,100 yuan today, with a total floating profit of 291,000 yuan during the three-day increase [2][5]. - The CICC New Medicine A Fund was established on May 14, 2019, with a current scale of 68.32 million yuan. Year-to-date, it has experienced a loss of 6.84%, ranking 4,764 out of 5,563 in its category; over the past year, it has gained 8.47%, ranking 3,376 out of 4,429; and since inception, it has achieved a return of 44.49% [2][5]. Fund Manager Information - The fund manager of CICC New Medicine A is Ding Tianyu, who has been in the position for 5 years and 89 days. The total asset size of the fund is 205 million yuan, with the best return during his tenure being 2.35% and the worst return being -30.51% [3][6][7].